Eradication of H. Pylori With the Regimen Individualized Susceptibility of H. Pylori to Clarithromycin Determined by the Mutation of 23S rRNA of H. Pylori

Eradication of H. Pylori With the Regimen Individualized Susceptibility of H. Pylori to Clarithromycin Determined by the Mutation of 23S rRNA of H. Pylori - Eradication of H. Pylori Therapy Individualized by the Mutation of 23S rRNA of H. Pylori (EHR)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022766

Enrollment

100

Registered

2016-07-01

Start date

2016-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients infected with H. pylori

Interventions

During the gastroscopy, gastric mucus samples are collected, from which DNA is extracted. The DNA samples are subjected the full-auto SNP analyzer and the from A to G mutation of 23s rRNA of H. pylori

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients infected with H. pylori are invited to the study. Patients not allergic to the any of the drugs used for eradication of H. pylori. Patients who has agreed to participate to the study.

Exclusion criteria

Exclusion criteria: Patients allergic to the any of the drugs used for eradication of H. pylori. Patients who do not agree to the study.

Design outcomes

Primary

Measure	Time frame
Eradication rates of H. pylori is assessed bythe 13C-urea breath test performed at 1 month after the therapy.	—

Secondary

Measure	Time frame
interview on the adverse events during the treatment, such as diarrhea, loose stool, abdominal pain and allergic reactions.	—

Countries

Japan

Contacts

Public ContactTakahisa Furuta

Hamamatsu University School of Medicine Center for Clinical Research

furuta@hama-med.ac.jp053-435-2850

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026